AVIR News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

AV

Mkt Cap

$347.0M

Volume

301.34K

Next Earnings

November 11th

Loading chart

AV

AVIRAtea Pharmaceuticals, Inc. Common Stock

AVIR

Pay with—

Available Balance0.00

AV

Mkt Cap

$363.3M

Volume

301.33K

Next Earnings

November 11th

Chart Financials Earnings News About Insider Filings

Atea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026Atea Pharmaceuticals announced Phase 1 results demonstrating that its fixed-dose combination regimen of bemnifosbuvir and ruzasvir (BEM/RZR) for hepatitis C virus treatment has a low risk of drug-drug interactions with commonly used medications like omeprazole and rosuvastatin. The company also presented preclinical data showing AT-587, a potential first-in-class direct-acting antiviral for hepatitis E virus, exhibits high antiviral potency and in vivo efficacy, with plans to initiate first-in-human studies mid-2026.GlobeNewswire Inc. · May 27, 2026

Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026Atea Pharmaceuticals announced preclinical results showing AT-587 and AT-2490 are potent inhibitors of Hepatitis E Virus (HEV), demonstrating 30-150 fold greater potency compared to sofosbuvir and ribavirin. The company plans to initiate Phase 1 clinical trials for AT-587 mid-2026, addressing an unmet medical need as no antivirals are currently approved for HEV treatment.GlobeNewswire Inc. · Feb 24, 2026

Atea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025Atea Pharmaceuticals presented modeling data showing their combination drug regimen of bemnifosbuvir and ruzasvir could potentially provide a short-duration, highly effective treatment for hepatitis C virus, with near-complete viral inhibition and a modeled cure time of 7-8 weeks.GlobeNewswire Inc. · Nov 7, 2025

Atea Pharmaceuticals to Host Third Quarter 2025 Financial Results and Business Update Conference Call on November 12, 2025Atea Pharmaceuticals will host a conference call on November 12, 2025, to discuss third quarter financial results and provide a business update, focusing on their antiviral drug development platform and HCV treatment research.GlobeNewswire Inc. · Nov 5, 2025

Atea Pharmaceuticals to Host Second Quarter 2025 Financial Results and Business Update Conference Call on August 7, 2025Atea Pharmaceuticals will host a conference call on August 7, 2025, to discuss second quarter 2025 financial results and provide a business update, focusing on their HCV treatment development program.GlobeNewswire Inc. · Jul 31, 2025

Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North AmericaAtea Pharmaceuticals has dosed the first patient in its global Phase 3 C-FORWARD trial evaluating a combination regimen for the treatment of hepatitis C virus (HCV). The regimen has the potential to be a best-in-class option with a short treatment duration, low risk of drug-drug interactions, and convenience.GlobeNewswire Inc. · Jun 24, 2025

Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025Atea Pharmaceuticals announced that it will present data from a Phase 2 clinical study of its regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) at the EASL Congress 2025. The regimen has the potential to be a best-in-class treatment option with a short duration, low risk of drug interactions, and convenience.GlobeNewswire Inc. · Apr 23, 2025

Atea Pharmaceuticals Announces Dosing of First Patient in C-BEYOND, Phase 3 Study Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C VirusAtea Pharmaceuticals has dosed the first patient in its Phase 3 trial evaluating a regimen of bemnifosbuvir and ruzasvir for the treatment of chronic hepatitis C virus (HCV). The regimen has the potential to be a best-in-class therapy with a short treatment duration, low risk of drug-drug interactions, and convenience.GlobeNewswire Inc. · Apr 9, 2025

Atea Pharmaceuticals Highlights Actions Underway to Enhance Shareholder ValueAtea Pharmaceuticals has taken several actions to enhance shareholder value, including a strategic review, cost-cutting measures, and the appointment of a new independent director.GlobeNewswire Inc. · Mar 26, 2025

Atea Pharmaceuticals Issues Statement Regarding Director NominationsAtea Pharmaceuticals, a clinical-stage biopharmaceutical company, has received a notice from a shareholder group, Bradley L. Radoff, that he intends to nominate three director candidates for election to the Atea Board of Directors at the company's 2025 Annual Meeting of Stockholders. Atea's Board and management team will evaluate the director candidates and make a formal recommendation in the company's proxy statement.GlobeNewswire Inc. · Mar 21, 2025

to start trading

AV

AVIRAtea Pharmaceuticals, Inc. Common Stock

AVIR

Pay with—

Available Balance0.00

Your PositionYou don't own any AVIR yet.

Related Tickers

Earnings